tirzepatide not on shortage list Eli Lilly's Weight-Loss Drug Zepbound Is Officially Over: FDA Zia - The recent news
Description
Data from the SURMOUNT clinical trial programme showed that tirzepatide produced greater average percentage body weight reductions than semaglutide in head-to-head comparisons, though individual responses vary
The primary outcome was to assess the proportion of time CGM values were in the target glucose range (71-140 mg/dL) at 52 weeks
Most common side effects diminish within one to two weeks as the body adapts
Possible Side Effects May include nausea, constipation, headache, or mild injection site discomfort
